Summary of Clinical Use

Pamrevlumab (research coded FG-3019) is being evaluated in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF), type 2 diabetes, diabetic nephropathy and diabetic kidney disease, pancreatic cancer [2,5], Duchenne muscular dystrophy [4] and Hepatitis B-induced liver fibrosis. Click here to link to ClinicalTrials.gov's listing of Phase 2 FG-3019 trials.

Mechanism Of Action and Pharmacodynamic Effects

Pamrevlumab acts as an anti-connective tissue growth factor agent to reduce extracellular matrix production, which can reverse the fibrotic process [1,3,6].